NeuroMab™ Anti-EPHA2 BBB Shuttle Antibody(NRZP-1022-ZP3855)

Product Overview

Description

Brain uptake of therapeutic antibodies is severely limited by their size. To achieve enhanced BBB crossing, Creative Biolabs developed a BBB shuttle antibody platform by utilizing the endogenous macromolecule transportation pathway, known as receptor-mediated transcytosis (RMT). The engineered antibody-based carrier is believed to significantly to increase the macromolecule brain entry to combat CNS diseases.
Notes: The BBB antibody is made-to order and available in a customized format. Please don't hesitate contact us for more details.

Species Reactivity

Human

Clonality

Monoclonal

Host Species

Humanized

Applications

In Vitro; Inhib; Cyt

Relevant Diseases

Glioblastoma Multiforme

Product Properties

Storage

Store at -20°C. Do not aliquot the antibody.

Research Use Only

For research use only

Target

EPHA2

Official Name

EPHA2

Full Name

EPH receptor A2 (ephrin type-A receptor 2)

Alternative Names

EPHA2; Epha2; AW545284; Eck; Myk2; Sek-2; Sek2; ARCC2; CTPA; CTPP1; CTRCT6; EPH receptor A2; ECK

Product Pictures

Figure 1 Kinetic analysis of EphA2 phosphorylation in MDA-MB-231 cells. WT wild-type untreated cells; MW molecular weight marker; P-EphA2 phosphorylated Epha2

Figure 2A Inhibition of EphA2 phosphorylation after EphrinA1/Fc induced NCI-H1299 cells (5A) and MDA-MB-231 cells (5B), respectively; WT wild-type untreated cells; MW molecular weight markers; P-EphA2 phosphorylation Normalized EphA2.

Figure 2B EphrinA1/Fc induced inhibition of EphA2 phosphorylation in NCI-H1299 cells (5A) and MDA-MB-231 cells (5B), respectively; WT wild-type untreated cells; MW molecular weight markers; P-EphA2 phosphorylation Normalized EphA2.

Cyt

Figure 3 Cytotoxic activity of hu2H11R35R74-PEG4-Mal-DM4 compared to hu2H11-PEG4-Mal-DM4 (small filled circles DAR=6.7; large filled circles DAR=7.0).

Figure 4 Time graph (semi-logarithmic scale) representing the mean plasma concentration of hu2H11-SPDB-DM4 following a single intravenous dose of 20 mg/kg immunoconjugate in HGS to male CD-1 mice (n=2 ). Total concentrations of human IgG (solid diamonds) and conjugated moieties (open squares) are shown.

Figure 5 Time plot (semi-logarithmic scale) representing mean plasma concentrations of hu2H11R35R74-PEG4-NHAc-DM4 (n=2) after single dose intravenous administration of 20 mg/kg immunoconjugate in HGS to male CD- 1 Mouse. Total concentrations of human IgG (solid diamonds) and conjugated moieties (open squares) are shown.

Figure 6A Bar graph representation of PK parameters of hu2H11R35R74-PEG4-NHAc-DM4 under various DARs, exposure to (AUC(0-inf); Figure 9A) and clearance (Cl; Figure 9B) of several ADCs DAR function following a single intravenous dose of 20 mg/kg of HGS immunoconjugate to male CD-1 mice (n=4).

Figure 6B PK parameters of hu2H11R35R74-PEG4-NHAc-DM4 in various DARs, exposed to (AUC(0-inf); Figure 9A) and cleared (Cl; Figure 9B) for several ADCs. DAR function after a single intravenous dose of 20 mg/kg of HGS immunoconjugate in male CD-1 mice (n=4).

Publications